Journal of Antimicrobial Chemotherapy (2001) 47, 811-818
© 2001 The British Society for Antimicrobial Chemotherapy
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae
Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
An in vitro pharmacokinetic model (IVPM) was used to simulate the human serum pharmacokinetics of moxifloxacin, levofloxacin and sparfloxacin, and to compare their pharmacodynamics against Streptococcus pneumoniae exhibiting a wide range of susceptibilities to fluoroquinolones. Logarithmic-phase cultures were exposed to peak concentrations achieved in human serum of moxifloxacin, levofloxacin or sparfloxacin with oral doses of 400, 500 and 200 mg, respectively. Human elimination pharmacokinetics were simulated, and viable bacterial counts were measured at 0, 1, 2, 4, 6, 8, 24 and 36 h. Moxifloxacin was rapidly bactericidal (>3 logs of killing) against all 10 S. pneumoniae strains, with 99.9% kills of eight strains occurring within 1–3 h after dosing. Maximum kills ranged from 5 to >6 logs. Moxifloxacin eradicated seven strains from the IVPM within 8 h of the first dose, and eradicated two other strains within 24 h. Although levofloxacin and sparfloxacin were also bactericidal against all 10 S. pneumoniae strains, the rates of killing were somewhat slower, with sparfloxacin exhibiting the slowest rate of kill. In summary, moxifloxacin's increased anti-pneumococcal potency compared with levofloxacin and its more favourable pharmacokinetics compared with sparfloxacin provided enhanced pharmacodynamic activity against some S. pneumoniae strains when maximum doses were simulated in an IVPM.
* Corresponding author. Tel: +1-402-280-1881; Fax: +1-402-280-1225; E-mail: pdlister{at}creighton.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Bhavnani, J. A. Passarell, J. S. Owen, J. S. Loutit, S. B. Porter, and P. G. Ambrose Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia Antimicrob. Agents Chemother., March 1, 2006; 50(3): 994 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wilson, L. Allegra, G. Huchon, J.-L. Izquierdo, P. Jones, T. Schaberg, and P.-P. Sagnier Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis Chest, March 1, 2004; 125(3): 953 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pea, F. Pavan, E. Nascimben, C. Benetton, P. G. Scotton, A. Vaglia, and M. Furlanut Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3104 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cha and M. J. Rybak Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1984 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, and K. E. Bowker Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1088 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lister Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones J. Antimicrob. Chemother., January 1, 2003; 51(1): 199 - 202. [Full Text] [PDF]
|
|